Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients-Reference-Cited by-同舟云学术

Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients

Published:2010-10-20 Issue:1 Volume:125 Page:127-136
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Warm Mathias,Kates Ronald,Overkamp Friedrich,Thomas Anke,Harbeck Nadia

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-010-1214-3.pdf

Reference33 articles.

1. Milano A, Dal Lago L, Sotiriou C et al (2006) What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer 42:2692–2705

2. Adamo V, Iorfida M, Montalto E et al (2007) Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. Ann Oncol 18:vi53–vi57

3. Kurokawa H, Arteaga CL (2003) ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanism. Clin Cancer Res 9:511S–515S

4. Howell A (2005) The future of fulvestrant (“Faslodex”). Cancer Treat Rev 31:S26–S33

5. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867–3873

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382;Oncogenesis;2018-07

2. Fulvestrant: a guide to its use in hormone receptor-positive metastatic breast cancer in postmenopausal women in the EU;Drugs & Therapy Perspectives;2013-12-21

3. Current World Literature;Current Opinion in Obstetrics & Gynecology;2012-02

4. Fulvestrant;Drugs;2011-02